Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections

Clinical Infectious Diseases

Volumn 65, Issue 3, 2017, Pages 495-500

  Tse, Brian N ^a   Adalja, Amesh A ^b,c   Houchens, Christopher ^a   Larsen, Joseph ^a   Inglesby, Thomas V ^b   Hatchett, Richard ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic resistance; antibodies; microbiome; nontraditional approaches; phage

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANTISENSE THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL MICROBIOME; BACTERIAL VIRULENCE; BACTERIOPHAGE; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; FECAL MICROBIOTA TRANSPLANTATION; MICROFLORA; PHAGE THERAPY; PROCEDURES; TRENDS;

ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MICROBIOTA; PHAGE THERAPY; THERAPEUTICS;

EID: 85027875281     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix320     Document Type: Article

References (25)

1. AMR Review. Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Resistance, 2016.
2. Pew Charitable Trusts. Antibiotics currently in clinical development. 2016. Available at: http://www.pewtrusts.org/~/media/assets/2016/05/antibiotics-currently-in-clinical-development.pdf. Accessed 4 November 2016.
3. Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: the need for a One Health-One Europe-One World Framework. Ministry of Health, the Netherlands. 2016. Available at: http://www.lse.ac.uk/LSEHealthAndSocialCare/pdf/Antibiotics-book-web.pdf Accessed 4 November 2016.
4. Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016; 535:85-93.
5. Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 535:56-64.
6. US Food and Drug Administration. Facilitating antibacterial drug development for patients with unmet need and developing antibacterial drugs that target a single species. 2016. Available at: http://www.fda.gov/Drugs/NewsEvents/ucm497650.htm. Accessed 3 January 2017.
7. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016; 6:26717.
8. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 2010; 8:317-27.
9. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016; 214:173-81.
10. Seres Therapeutics. Seres therapeutics announces interim results from SER-109 phase 2 ECOSPOR study in multiply recurrent Clostridium difficile infection. 2016. Available at: http://ir.serestherapeutics.com/phoenix.zhtml?c= 254006&p=irol-newsArticle&ID=2190006. Accessed 14 March 2017.
11. Zumla A, Rao M, Dodoo E, Maeurer M. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med 2016; 14:89.
12. Wallis RS, Zumla A. Vitamin D as adjunctive host-directed therapy in tuberculosis: a systematic review. Open Forum Infect Dis 2016; 3:ofw151.
13. Silva ON, de la Fuente-Núñez C, Haney EF, et al. An anti-infective synthetic peptide with dual antimicrobial and immunomodulatory activities. Sci Rep 2016; 6:35465.
14. Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 2016; 16:239-51.
15. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6:17-27.
16. Swatton JE, Davenport PW, Maunders EA, Griffin JL, Lilley KS, Welch M. Impact of azithromycin on the quorum sensing-controlled proteome of Pseudomonas aeruginosa. PLoS One 2016; 11:e0147698.
17. Perry JA, Koteva K, Verschoor CP, Wang W, Bowdish DM, Wright GD. A macrophage-stimulating compound from a screen of microbial natural products. J Antibiot 2015; 68:40-6.
18. Olson KM, Starks CM, Williams RB, et al. Novel pentadecenyl tetrazole enhances susceptibility of methicillin-resistant Staphylococcus aureus biofilms to gentamicin. Antimicrob Agents Chemother 2011; 55:3691-5.
19. Vermote A, Brackman G, Risseeuw MD, Coenye T, Van Calenbergh S. Design, synthesis and biological evaluation of novel hamamelitannin analogues as potentiators for vancomycin in the treatment of biofilm related Staphylococcus aureus infections. Bioorg Med Chem 2016; 24:4563-75.
20. de la Fuente-Núñez C, Cardoso MH, de Souza Candido E, Franco OL, Hancock EW. Synthetic antibiofilm peptides. Biochim Biophys Acta 2016; 1858:1061-9.
21. Reffuveile F, de la Fuente-Núñez C, Mansour S, Hancock REW. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother 2014; 58:5363-71.
22. Rudilla H, Fusté E, Cajal Y, Rabanal F, Vinuesa T, Viñas M. Synergistic antipseudomonal effects of synthetic peptide AMP38 and carbapenems. Molecules 2016; 21:1223-34.
23. Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 2014; 32:1146-50.
24. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 2014; 32:1141-5.
25. Sully EK, Geller BL. Antisense antimicrobial therapeutics. Curr Opin Microbiol 2016; 33:47-55.